/PRNewswire/ The "Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence.
It is estimated that the Biodefense Market is anticipated to reach US$ 32.99 billion by 2033 after being valued at US$ 16.31 billion in 2023. This market is projected to expand at a CAGR of 7.3% during the analysis period. The growing demand for vaccines, drugs, and medical devices provides companies with opportunit.
In recent years, the biodefense market has experienced significant growth due to increased government funding for biodefense programs and growing public.
8 For years, scientists have warned the Nipah virus a brain-swelling disease 75 times more deadly than COVID could be the next pandemic. Knowing that this fruit bat-borne virus has the potential to trigger an epidemic, researchers at the Uniformed Services University (USU) have long studied the virus and recently reported on the development of a single-dose vaccine that, in preclinical trials, has proven effective against it as early as seven days after immunization.
The Nipah virus first emerged in the late 1990s, causing serious disease outbreaks in humans and livestock in Malaysia and Singapore. More frequent and recent Nipah outbreaks in Bangladesh, the Philippines and India have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission, and greater than 75 percent case fatality rates among humans (the SARS-CoV-2 coronavirus that causes COVID and a fatality rate of less than one percent). Much like Nipah, the closely-r